PRGO Stock Analysis: Perrigo | NYSE
Drug Manufacturers - Specialty & Generic | NYSE, USA | Market Cap: 1.377m USD | 12M Return: -56% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 39.7M
EPS Trend: 9.5%
Qual. Beats: 0
Rev. Trend: -97.1%
Qual. Beats: -1
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Perrigo Company plc (NYSE: PRGO) is a Dublin-based provider of over-the-counter (OTC) consumer self-care products, operating through Consumer Self-Care Americas and Consumer Self-Care International segments. Founded in 1887 and headquartered in Ireland, the company sells branded and private-label health and wellness items across upper respiratory, nutrition (including infant formula and electrolyte beverages), digestive health, pain and sleep, oral care, skin care, womens health, and vitamins/minerals/supplements categories, under brands such as Mederma, Plackers, REACH, Nasonex, Prevacid24HR, Opill, Solpadeine, and ellaOne.
Distribution spans retail drug, supermarket, and mass merchandise chains, e-commerce, wholesalers, pharmacies, and para-pharmacies, with the company also offering contract manufacturing services. Perrigo is widely recognized as one of the worlds largest manufacturers of private-label/store-brand OTC products, a business model in which retailers sell the companys formulations under their own labels, complementing its portfolio of owned brands.
- Opill OTC contraceptive adoption drives segment growth
- Store brand pricing pressure impacts Consumer Self-Care margins
- European segment revenue declines on weak demand
| Net Income: -1.82b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA -0.51 > 1.0 |
| NWC/Revenue: 41.04% < 20% (prev 33.66%; Δ 7.38% < -1%) |
| CFO/TA 0.02 > 3% & CFO 189.4m > Net Income -1.82b |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.72 > 1.5 & < 3 |
| Outstanding Shares: last quarter (138.7m) vs 12m ago 0.73% < -2% |
| Gross Margin: 34.17% > 18% (prev 36.38%; Δ -2.21% > 0.5%) |
| Asset Turnover: 47.10% > 50% (prev 44.42%; Δ 2.68% > 0%) |
| Interest Coverage Ratio: -9.44 > 6 (EBIT TTM -1.55b / Interest Expense TTM 164.3m) |
| A: 0.21 (Total Current Assets 2.71b - Total Current Liabilities 997.6m) / Total Assets 7.98b |
| B: -0.51 (Retained Earnings -4.08b / Total Assets 7.98b) |
| C: -0.17 (EBIT TTM -1.55b / Avg Total Assets 8.87b) |
| D: 0.46 (Book Value of Equity 2.50b / Total Liabilities 5.48b) |
| Altman-Z'' = -0.95 = CCC |
| DSRI: 1.06 (Receivables 732.8m/716.8m, Revenue 4.18b/4.34b) |
| GMI: 1.06 (GM 36.38% / 34.17%) |
| AQI: 0.84 (AQ_t 0.53 / AQ_t-1 0.63) |
| SGI: 0.96 (Revenue 4.18b / 4.34b) |
| TATA: -0.25 (NI -1.82b - CFO 189.4m) / TA 7.98b) |
| Beneish M = -3.06 (Cap -4..+1) = AA |
As of July 05, 2026, the stock is trading at USD 11.02 with a total of 3,336,000 shares traded. Over the past week, the price has changed by +13.84%, over one month by +5.35%, over three months by +6.77% and over the past year by -56.02%.
Current recommended Stop Loss: 10.00 (which is 9.3% or 2 ATR below the current price).
Perrigo has received a consensus analysts rating of 3.80. Therefore, it is recommended to hold PRGO.
- StrongBuy: 1
- Buy: 2
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 16.5 | 49.7% |
P/E Forward = 4.6926
P/S = 0.3295
P/B = 0.551
P/EG = 1.1418
Revenue TTM = 4.18b USD
EBIT TTM = -1.55b USD
EBITDA TTM = -1.24b USD
Long Term Debt = 3.62b USD (from longTermDebt, last quarter)
Short Term Debt = 37.5m USD (from shortTermDebt, last quarter)
Debt = 3.98b USD (from shortLongTermDebtTotal, last quarter) + Leases 173.0m
Net Debt = 3.62b USD (calculated: Debt 3.98b - CCE 357.2m)
Enterprise Value = 5.00b USD (1.38b + Debt 3.98b - CCE 357.2m)
Interest Coverage Ratio = -9.44 (Ebit TTM -1.55b / Interest Expense TTM 164.3m)
EV/FCF = 46.41x (Enterprise Value 5.00b / FCF TTM 107.7m)
FCF Yield = 2.15% (FCF TTM 107.7m / Enterprise Value 5.00b)
FCF Margin = 2.58% (FCF TTM 107.7m / Revenue TTM 4.18b)
Net Margin = -43.50% (Net Income TTM -1.82b / Revenue TTM 4.18b)
Gross Margin = 34.17% ((Revenue TTM 4.18b - Cost of Revenue TTM 2.75b) / Revenue TTM)
Gross Margin QoQ = 33.58% (prev 32.64%)
Tobins Q-Ratio = 0.63 (Enterprise Value 5.00b / Total Assets 7.98b)
Interest Expense / Debt = 4.13% (Interest Expense 164.3m / Debt 3.98b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -1.22b (EBIT -1.55b * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.72 (Total Current Assets 2.71b / Total Current Liabilities 997.6m)
Debt / Equity = 1.59 (Debt 3.98b / totalStockholderEquity, last quarter 2.50b)
Debt / EBITDA = -2.92 (negative EBITDA) (Net Debt 3.62b / EBITDA -1.24b)
Debt / FCF = 33.62 (Net Debt 3.62b / FCF TTM 107.7m)
Total Stockholder Equity = 3.59b (last 4 quarters mean from totalStockholderEquity)
RoA = -20.49% (Net Income -1.82b / Total Assets 7.98b)
RoE = -50.65% (Net Income TTM -1.82b / Total Stockholder Equity 3.59b)
RoCE = -21.50% (EBIT -1.55b / Capital Employed (Equity 3.59b + L.T.Debt 3.62b))
RoIC = -17.97% (negative operating profit) (NOPAT -1.22b / Invested Capital 6.81b)
WACC = 4.45% (E(1.38b)/V(5.36b) * Re(7.90%) + D(3.98b)/V(5.36b) * Rd(4.13%) * (1-Tc(0.21)))
Discount Rate = 7.90% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 80.90 | Cagr: 1.04%
[DCF] Terminal Value 73.10% ; FCFF base≈137.1m ; Y1≈120.2m ; Y5≈97.1m
[DCF] Fair Price = N/A (negative equity: EV 1.56b - Net Debt 3.62b = -2.06b; debt exceeds intrinsic value)
EPS Correlation: 9.54 | EPS CAGR: 0.84% | SUE: 0.55 | # QB: 0
Revenue Correlation: -97.15 | Revenue CAGR: -3.91% | SUE: -2.60 | # QB: -1
EPS current Quarter (2026-06-30): EPS=0.36 | Chg30d=+0.00% | Revisions=-50% | Analysts=4
EPS next Quarter (2026-09-30): EPS=0.57 | Chg30d=+0.00% | Revisions=-17% | Analysts=4
EPS current Year (2026-12-31): EPS=2.11 | Chg30d=+0.00% | Revisions=-17% | GrowthEPS=-23.4% | GrowthRev=-4.6%
EPS next Year (2027-12-31): EPS=2.36 | Chg30d=+0.00% | Revisions=+0% | GrowthEPS=+12.0% | GrowthRev=+1.0%
[Analyst] Revisions Ratio: -31% (up=4, down=9)